A Case Report : Modality Treatment With Mineralcorticoid And Radikal Reseksi To Total Reseksi In Pediatric Brain Tumor
Keywords:
Massa intracranial, Total Reseksi, Dexamethasone, MineralcorticoidAbstract
Brain tumor are the second most common neoplasm and the most common solid tumor in children. Fifty percent to 60% of childhood brain tumors originate in the posterior fossa. These include medulloblastomas, cerebellar astrocytomas, and fourth ventricle ependymomas. The remaining 40% to 50% of childhood brain tumors are supratentorial and include astrocytoma, hypothalamic and optic pathway tumors, and craniopharyngiomas. A 19 year old child came to the hospital emergency room with complaints of dizziness. Dizziness is accompanied by headaches that dissapearing. Complaints have been felt since about half a year but have worsened for one week before at emergency room. While being treated at the hospital, the patient experienced a seizure once, when the seizure was felt for 2 minutes, it was a whole body type of seizure. Patients also experience nausea and decreased appetite. Consciousness is still fully conscious. In this case, patien can be treatment IVFD Ringer Lactate 135 cc/hour, Metamizole 250 mg/1 ml /8 hour IV, Diphenhidramin 5 mg /12 hour IV, Dexamethasone 5 mg /8 hour IV, Piracetam 500 mg/12 hour IV. In this case, Dexamethasone therapy is given which is the corticosteroid of choice in these patients because of its low mineralocorticoid activity and only reduces the symptoms caused optimally. The goal is to reduce neurological symptoms but with a dose that is lowered slowly. The main treatment is still tumor resection with neurosurgeon.
References
Albright. (1993). Pediatric brain tumors. CA Cancer J Clin.
Johnson, Kimberly J., Cullen, Jennifer, Barnholtz-Sloan, Jill S., Ostrom, Quinn T., Langer, Chelsea E., Turner, Michelle C., McKean-Cowdin, Roberta, Fisher, James L., Lupo, Philip J., Partap, Sonia, Schwartzbaum, Judith A., & Scheurer, Michael E. (2014). Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review. Cancer Epidemiology, Biomarkers & Prevention, 23(12), 2716–2736. https://doi.org/10.1158/1055-9965.EPI-14-0207
Liu, Shiyu, Shi, Weiyan, Zhao, Qin, Zheng, Zhuangzhuang, Liu, Zijing, Meng, Lingbin, Dong, Lihua, & Jiang, Xin. (2021). Progress and prospect in tumor treating fields treatment of glioblastoma. Biomedicine & Pharmacotherapy, 141, 111810. https://doi.org/10.1016/j.biopha.2021.111810
Lombardi, Giuseppe, Corona, Giuseppe, Bellu, Luisa, Puppa, Alessandro Della, Pambuku, Ardi, Fiduccia, Pasquale, Bertorelle, Roberta, Gardiman, Marina Paola, D’Avella, Domenico, Toffoli, Giuseppe, & Zagonel, Vittorina. (2015). Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma. The Oncologist, 20(5), 562–567. https://doi.org/10.1634/theoncologist.2014-0266
Lukas, Rimas V, Wainwright, Derek A., Ladomersky, Erik, Sachdev, Sean, Sonabend, Adam M., & Stupp, Roger. (2019). Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park, NY), 33(3), 91. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278092/
Mallick, Supriya, Benson, Rony, Hakim, Abdul, & Rath, Goura K. (2016). Management of glioblastoma after recurrence: A changing paradigm. Journal of the Egyptian National Cancer Institute, 28(4), 199–210. https://doi.org/10.1016/j.jnci.2016.07.001
Mondal, Abir, Kumari Singh, Divya, Panda, Suchismita, & Shiras, Anjali. (2017). Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in Glioma. Frontiers in Oncology, 7, 1–8. https://doi.org/10.3389/fonc.2017.00144
Mrugala, Maciej M. (2013). Advances and challenges in the treatment of glioblastoma: a clinician’s perspective. Discovery Medicine, 15(83), 221–230. Retrieved from https://www.discoverymedicine.com/Maciej-M-Mrugala/2013/04/25/advances-and-challenges-in-the-treatment-of-glioblastoma-a-clinicians-perspective/
Omuro, Antonio. (2013). Glioblastoma and Other Malignant Gliomas. JAMA, 310(17), 1842–1850. https://doi.org/10.1001/jama.2013.280319
Opoku-Darko, Michael, Amuah, Joseph E., & Kelly, John J. P. (2018). Surgical resection of anterior and posterior butterfly glioblastoma. World Neurosurgery, 110, e612–e620. https://doi.org/10.1016/j.wneu.2017.11.059
Ostrom, Quinn T., Fahmideh, Maral Adel, Cote, David J., Muskens, Ivo S., Schraw, Jeremy M., Scheurer, Michael E., & Bondy, Melissa L. (2019). Risk factors for childhood and adult primary brain tumors. Neuro-Oncology, 21(11), 1357–1375. https://doi.org/10.1093/neuonc/noz123
Ozdemir-Kaynak, Elif, Qutub, Amina A., & Yesil-Celiktas, Ozlem. (2018). Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy. Frontiers in Physiology, 9. https://doi.org/10.3389/fphys.2018.00170
Posti, J. P., Bori, M., Kauko, T., Sankinen, M., Nordberg, J., Rahi, M., Frantzén, J., Vuorinen, V., & Sipilä, J. O. T. (2015). Presenting symptoms of glioma in adults. Acta Neurologica Scandinavica, 131(2), 88–93. https://doi.org/10.1111/ane.12285
Robertson, PL. (1998). Pediatric brain tumors. Prim Care.
Sasmita, Andrew Octavian, Wong, Ying Pei, & Ling, Anna Pick Kiong. (2018). Biomarkers and therapeutic advances in glioblastoma multiforme. Asia-Pacific Journal of Clinical Oncology, 14(1), 40–51. https://doi.org/10.1111/ajco.12756
Seidlitz, Annekatrin, Siepmann, Timo, Löck, Steffen, Juratli, Tareq, Baumann, Michael, & Krause, Mechthild. (2015). Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. Radiation Oncology, 10(1), 172. https://doi.org/10.1186/s13014-015-0478-5
Silantyev, Artemiy, Falzone, Luca, Libra, Massimo, Gurina, Olga, Kardashova, Karina, Nikolouzakis, Taxiarchis, Nosyrev, Alexander, Sutton, Christopher, Mitsias, Panayiotis, & Tsatsakis, Aristides. (2019). Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. Cells, 8(8), 863. https://doi.org/10.3390/cells8080863
Stoyanov, George S., Dzhenkov, Deyan, Ghenev, Peter, Iliev, Bogomil, Enchev, Yavor, & Tonchev, Anton B. (2018). Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. Medical Oncology, 35(3), 27. https://doi.org/10.1007/s12032-018-1083-x
Tan, Aaron C., Ashley, David M., López, Giselle Y., Malinzak, Michael, Friedman, Henry S., & Khasraw, Mustafa. (2020). Management of glioblastoma: State of the art and future directions. CA: A Cancer Journal for Clinicians, 70(4), 299–312. https://doi.org/10.3322/caac.21613
Thakkar, Jigisha P., Dolecek, Therese A., Horbinski, Craig, Ostrom, Quinn T., Lightner, Donita D., Barnholtz-Sloan, Jill S., & Villano, John L. (2014). Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology, Biomarkers & Prevention, 23(10), 1985–1996. https://doi.org/10.1158/1055-9965.EPI-14-0275
Udaka, Yoko T., & Packer, Roger J. (2018). Pediatric Brain Tumors. Neurologic Clinics, 36(3), 533–556. https://doi.org/10.1016/j.ncl.2018.04.009
Wilson, TaylorA, Karajannis, MatthiasA, & Harter, DavidH. (2014). Glioblastoma multiforme: State of the art and future therapeutics. Surgical Neurology International, 5(1), 64. https://doi.org/10.4103/2152-7806.132138
Wirsching, Hans Georg, Galanis, Evanthia, & Weller, Michael. (2016). Glioblastoma. In Handbook of Clinical Neurology (pp. 381–397). https://doi.org/10.1016/B978-0-12-802997-8.00023-2
Witthayanuwat, Supapan, Pesee, Montien, Supaadirek, Chunsri, Supakalin, Narudom, Thamronganantasakul, Komsan, & Krusun, Srichai. (2018). Survival analysis of glioblastoma multiforme. Asian Pacific Journal of Cancer Prevention: APJCP, 19(9), 2613. https://doi.org/10.22034/APJCP.2018.19.9.2613
Zhao, Hongyu, Cai, Weisong, Su, Shitao, Zhi, Debao, Lu, Jie, & Liu, Shuo. (2014). Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects. Tumor Biology, 35(4), 3875–3880. https://doi.org/10.1007/s13277-013-1514-4
